<![CDATA[Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC]]>
Regulatorypositivepembrolizumabenfortumab vedotinPositive
AI Analysis
Summary
Pembrolizumab plus enfortumab vedotin received a positive CHMP opinion for perioperative use in resectable muscle-invasive bladder cancer, supporting approval regardless of cisplatin eligibility status.
Outcome Details
Positive CHMP opinion for perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility
Importance:8/10
Sentiment:
0.80
CHMP opinionbladder cancercombination therapyregulatory approvalperioperative treatment
Related Companies
Read the original article
Published by Cancer Network on September 19, 2026 4:00 PM